John Kelly - CR Bard Independent Director

Director

Mr. John C. Kelly is Independent Director of the Company. He is Former Senior Vice President, Finance of Pfizer Inc. . Mr. Kelly served as Senior Vice President, Finance of Pfizer Inc. from October 2009 to February 2010, having been Vice President and Controller of Wyeth since March 2008. Mr. Kelly held various other positions, including Vice President, Finance Operations, since joining Wyeth in 2002. He is also a director of The Medicines Company since 2009.
Age 73
Tenure 15 years
Professional MarksMBA
Phone908 277-8000
Webwww.crbard.com
Kelly was nominated to serve an additional term as a director as a result of over 45 years of experience in accounting and finance, as well as his background in healthcare. Prior to joining Wyeth, where he handled a wide range of assignments in finance, he spent more than 35 years in public accounting at Arthur Andersen in various leadership capacities, including as the partner in charge of audit and business consulting practices in the New York metropolitan area. He is a certified public accountant and was an elected member of the Council of the American Institute of Certified Public Accountants. He earned both his B.S. in business administration and M.B.A. in international finance from Seton Hall University.

John Kelly Latest Insider Activity

Tracking and analyzing the buying and selling activities of John Kelly against CR Bard stock is an integral part of due diligence when investing in CR Bard. John Kelly insider activity provides valuable insight into whether CR Bard is net buyers or sellers over its current business cycle. Note, CR Bard insiders must abide by specific rules, including filing SEC forms every time they buy or sell CR Bard'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

CR Bard Management Efficiency

CR Bard's management efficiency ratios could be used to measure how well CR Bard manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 1.64 B in debt with debt to equity (D/E) ratio of 81.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. CR Bard has a current ratio of 1.69, which is typical for the industry and considered as normal. Debt can assist CR Bard until it has trouble settling it off, either with new capital or with free cash flow. So, CR Bard's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CR Bard sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BCR to invest in growth at high rates of return. When we think about CR Bard's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Stephen GillettChipotle Mexican Grill
39
Darlene FriedmanChipotle Mexican Grill
72
Mark KalowWestrock Coffee
59
Scott MawChipotle Mexican Grill
54
Hong DuWeibo Corp
45
Michael BrownQ2 Holdings
44
Scott FordWestrock Coffee
61
Yong ZhangWeibo Corp
46
Daniel BrestleDine Brands Global
74
Susan CollynsDine Brands Global
54
Kimbal MuskChipotle Mexican Grill
45
Ali NamvarChipotle Mexican Grill
50
Lynn AtchisonQ2 Holdings
58
Lilian TomovichDine Brands Global
53
Patrick RoseDine Brands Global
73
Michael MaplesQ2 Holdings
75
Caroline NahasDine Brands Global
72
Edward RoffmanWestrock Coffee
64
Robin HickenlooperChipotle Mexican Grill
42
Pehong ChenWeibo Corp
59
Jeffrey DiehlQ2 Holdings
50
C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard (BCR) is traded on New York Stock Exchange in USA and employs 14,900 people.

Management Performance

CR Bard Leadership Team

Elected by the shareholders, the CR Bard's board of directors comprises two types of representatives: CR Bard inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BCR. The board's role is to monitor CR Bard's management team and ensure that shareholders' interests are well served. CR Bard's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CR Bard's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Beasley, Group President
Patricia Christian, Vice President - Quality, Regulatory and Medical Affairs
Sharon Alterio, Group Vice President
Todd Garner, Vice President - Investor Relations
Marc Breslawsky, Independent Director
John Weiland, President, COO and Director
John DeFord, Senior Vice President - Science, Technology and Clinical Affairs
Frank Lupisella, Principal Accounting Officer, VP and Controller
Betty Larson, Vice President Human Resources.
John Groetelaars, Group Vice President
Tony White, Independent Director
Gerard Porreca, Vice President - Quality, Regulatory and Medical Affairs
Robert Davis, Director
Anthony Welters, Independent Director
Gail Naughton, Independent Director
John Kelly, Independent Director
Tommy Thompson, Independent Director
Samrat Khichi, Senior Vice President General Counsel, Secretary
Sharon Luboff, Group Vice President
Herbert Henkel, Lead Independent Director
Christopher Holland, CFO and Sr. VP
David Melcher, Director
Jim Beasley, Group Pres
Timothy Collins, Group Pres
Timothy Ring, Chairman, CEO and Chairman of Executive Committee
David Barrett, Independent Director

BCR Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CR Bard a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with CR Bard

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CR Bard position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CR Bard will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the CR Bard information on this page should be used as a complementary analysis to other CR Bard's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Consideration for investing in BCR Stock

If you are still planning to invest in CR Bard check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CR Bard's history and understand the potential risks before investing.
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Volatility Analysis
Get historical volatility and risk analysis based on latest market data